A sharp decline in COVID-19 cases is leading to a newfound risk-on mode for the stock market, Fundstrat s Tom Lee said in a note on Thursday. The bullish groundswell
Investors should stay pro-risk and continue buying stocks as a synchronized global expansion takes hold thanks to mass vaccinations, JPMorgan s Marko Kolanovic
» Wildly overvalued : A former Wall Street chief strategist says it s time for stock bulls to sell their holdings - and warns of a particularly vicious comeuppance for small-caps Wildly overvalued : A former Wall Street chief strategist says it s time for stock bulls to sell their holdings - and warns of a particularly vicious comeuppance for small-caps
Matthew FoxJan 10, 2021, 20:23 IST
Traders and financial professionals work ahead of the closing bell on the floor of the New York Stock Exchange (NYSE)Drew Angerer/Getty Images
Investors should sell their long positions in stocks as the market is wildly overvalued, AlphaOmega Advisors Peter Cecchini said in a note on Wednesday.
Learn about DVN (XNYS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a 14-day free trial to Morningstar Premium to unlock our take on DVN.
Feb 4, 2021
No-moat Change Healthcare released third-quarter results after the close Feb. 3 that were largely in line with expectations. Overall revenue was slightly short of consensus estimates as tracked by FactSet. The slight top-line shortfall was somewhat offset by lower-than-expected operating expenses, likely a result of the rightsizing ahead of the pending acquisition. Last month, UnitedHealth Group’s services arm, Optum, announced plans to acquire Change Healthcare for $25.75 per share. Management continues to anticipate the close to occur in the second half of the year, and we do not see any notable hurdles beyond the customary regulatory approvals. Strategically, we believe the announced acquisition better leverages the diverse business components developed by Change Healthcare with the captive payer audience of UnitedHealthcare. This transaction also alleviates investor scrutiny of the current management team s rollup strategy and resulting (significant) deb